Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584937 | 1.00 | CHRNA7 (0.41) | CHRNA7EPHX2CYP2C9CYP2J2CHRM3 | |
| SCHEMBL6586914 | 0.88 | EPHX2 (0.44) | CHRNA7EPHX2CYP2C9CYP2J2PRMT5 | |
| SCHEMBL6586909 | 0.88 | EPHX2 (0.44) | CHRNA7EPHX2CYP2C9CYP2J2PRMT5 | |
| SCHEMBL6586275 | 0.88 | EPHX2 (0.47) | CHRNA7EPHX2CYP2C9CYP2J2PRMT5 | |
| SCHEMBL6585234 | 0.88 | EPHX2 (0.47) | CHRNA7EPHX2CYP2C9CYP2J2PRMT5 | |
| SCHEMBL6585239 | 0.88 | EPHX2 (0.47) | CHRNA7EPHX2CYP2C9CYP2J2PRMT5 | |
| SCHEMBL6585993 | 0.84 | CCR3 (0.45) | CHRNA7EPHX2 | |
| SCHEMBL6585997 | 0.84 | CCR3 (0.45) | CHRNA7EPHX2 | |
| SCHEMBL6584370 | 0.80 | CHRNA7 (0.45) | CHRNA7EPHX2PRMT5WDR77ACACB | |
| SCHEMBL6584366 | 0.80 | CHRNA7 (0.45) | CHRNA7EPHX2PRMT5WDR77ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1049671-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RES LTD (GB) | 2004-04-21 | — | — | EP | claimed |
| US-6514961-B1 | Such as anxiety and all forms of epilepsy, particularly in humans | VERNALIS RESEARCH LIMITED (GB) | 2003-02-04 | — | — | US | claimed |
| EP-1196166-A1 | AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2002-04-17 | — | — | EP | claimed |
| WO-2001007043-A1 | AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | claimed |
| EP-1049671-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | claimed |
| WO-1999037614-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | claimed |